stockrowSarepta Therapeutics, Inc.
SRPT Healthcare Biotechnology
Sarepta Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.2 billion, up 15.6% from fiscal 2024.
- Revenue
- −4.51%
- EPS
- +46.0%
- Free cash flow
- +231.8%
- Total debt
- −17.2%
Quarter to September 2026, against a year earlier
Follow SRPT
Alert me
Sarepta Therapeutics, Inc. (SRPT) Operating cash flow
Sarepta Therapeutics, Inc.'s operating cash flow for fiscal 2025 was −$205.5M, compared with −$205.8M in fiscal 2024. Over the twelve months to 30 September 2026 it was $185.6M. Over the past ten years it has ranged from −$501.0M (fiscal 2023) to $107.5M (fiscal 2020); the current reading is higher than 82% of that period. Sarepta Therapeutics, Inc. ranks 22nd of 603 Biotechnology companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | −$205.5M | — |
| FY2024 | −$205.8M | — |
| FY2023 | −$501.0M | — |
| FY2022 | −$325.3M | — |
| FY2021 | −$443.2M | — |
| FY2020 | $107.5M | — |
| FY2019 | −$456.5M | — |
| FY2018 | −$388.7M | — |
| FY2017 | −$232.0M | — |
| FY2016 | −$245.8M | — |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Sep 2026 | $60.0M | (69.57%) |
| Jun 2026 | $197.1M | — |
| Mar 2026 | −$202.7M | — |
| Dec 2025 | $131.2M | — |
| 43 more quarters | Free account |
Against its own ten years
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| HRMY Harmony Biosciences Holdings, Inc. compare | $323.0M |
| SRPT Sarepta Therapeutics, Inc. | $185.6M |
| MRVI Maravai LifeSciences Holdings, Inc. compare | −$5.1M |
| TRVI Trevi Therapeutics, Inc. compare | −$52.6M |
| MESO Mesoblast Limited compare | −$83.5M |
| MAZE Maze Therapeutics, Inc. compare | −$106.5M |
| TRAX First Tracks Biotherapeutics, Inc. compare | −$112.2M |
| VIR Vir Biotechnology, Inc. compare | −$141.0M |
| REPL Replimune Group, Inc. compare | −$245.5M |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item